The Food and Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new indications. In addition to plaque psoriasis, Bimzelx, a humanized interleukin-17A and ...
FDA has approved Tagrisso for the treatment of adult patients with locally advanced, unresectable NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based ...
The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.